JP2022141811A5 - - Google Patents

Download PDF

Info

Publication number
JP2022141811A5
JP2022141811A5 JP2022114274A JP2022114274A JP2022141811A5 JP 2022141811 A5 JP2022141811 A5 JP 2022141811A5 JP 2022114274 A JP2022114274 A JP 2022114274A JP 2022114274 A JP2022114274 A JP 2022114274A JP 2022141811 A5 JP2022141811 A5 JP 2022141811A5
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
heteroaryl
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022114274A
Other languages
English (en)
Japanese (ja)
Other versions
JP7549627B2 (ja
JP2022141811A (ja
Filing date
Publication date
Priority claimed from GBGB1509338.8A external-priority patent/GB201509338D0/en
Application filed filed Critical
Publication of JP2022141811A publication Critical patent/JP2022141811A/ja
Publication of JP2022141811A5 publication Critical patent/JP2022141811A5/ja
Application granted granted Critical
Publication of JP7549627B2 publication Critical patent/JP7549627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022114274A 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 Active JP7549627B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1509338.8 2015-05-29
GBGB1509338.8A GB201509338D0 (en) 2015-05-29 2015-05-29 Combination therapy
GBGB1516442.9A GB201516442D0 (en) 2015-05-29 2015-09-16 Combination therapy
GB1516442.9 2015-09-16
JP2020038089A JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020038089A Division JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Publications (3)

Publication Number Publication Date
JP2022141811A JP2022141811A (ja) 2022-09-29
JP2022141811A5 true JP2022141811A5 (enExample) 2023-04-10
JP7549627B2 JP7549627B2 (ja) 2024-09-11

Family

ID=53677482

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513923A Active JP6795585B2 (ja) 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2022114274A Active JP7549627B2 (ja) 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018513923A Active JP6795585B2 (ja) 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Country Status (5)

Country Link
US (4) US20180153888A1 (enExample)
EP (2) EP3302481A1 (enExample)
JP (3) JP6795585B2 (enExample)
GB (2) GB201509338D0 (enExample)
WO (1) WO2016193680A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
AU2018244925A1 (en) 2017-03-31 2019-11-21 The Curators Of The University Of Missouri Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2019039525A1 (ja) * 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
BR112020026641A2 (pt) * 2018-06-27 2021-03-30 Oscotec Inc. Derivados de piridopirimidinona para o uso como inibidores de axl
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) * 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
EP4359439A1 (en) 2021-06-24 2024-05-01 Yeda Research and Development Co. Ltd Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
KR20240156104A (ko) * 2023-04-21 2024-10-29 아주대학교산학협력단 면역 관문 억제제 저항성 극복을 위한 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2226211A1 (de) 1972-05-30 1973-12-13 Basf Ag N-substituierte iminocumarinfarbstoffe
WO2000054795A1 (en) * 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6149495A (en) 1999-03-15 2000-11-21 Austin; Joseph James Confetti and theatrical snow delivery device
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
EP1563094A4 (en) 2002-10-29 2007-04-25 Rigel Pharmaceuticals Inc MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS
EP1922310A2 (en) 2005-09-07 2008-05-21 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101646449A (zh) 2006-10-10 2010-02-10 斯奎科公司 用于治疗和诊断癌症的组合物和方法
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5546250B2 (ja) * 2006-12-29 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な多環式ヘテロアリール置換トリアゾール
DK2114955T3 (da) 2006-12-29 2013-05-06 Rigel Pharmaceuticals Inc Broforbundet, bicyklisk aryl og broforbundet, bicyklisk heteroaryl subsitiuerede triazoler, der er anvendelige som axl-inhibitorer
WO2008083354A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008086342A2 (en) 2007-01-09 2008-07-17 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20100255004A1 (en) 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
CA2682733A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
SI2205592T1 (sl) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
CN101939336B (zh) 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
TW200936160A (en) 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
HUE032735T2 (en) 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
US8735064B2 (en) 2007-12-24 2014-05-27 Bergenbio As Methods for creating and identifying functional RNA interference elements
PT2387395E (pt) * 2009-01-16 2015-02-04 Rigel Pharmaceuticals Inc Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático
MX2011011825A (es) 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
EP2482849B1 (en) * 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2011159980A1 (en) * 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
CN103221428B (zh) * 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
WO2012175692A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
MX2017007321A (es) 2014-12-02 2017-08-25 Celgene Corp Terapias de combinacion.
AU2015366213B2 (en) * 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy

Similar Documents

Publication Publication Date Title
JP2022141811A5 (enExample)
JP2020105211A5 (enExample)
RU2011132118A (ru) Ингибиторы axl для применения в комбинированной терапии для предотвращения, устранения или лечения метастизирующего рака
AU2015243379B2 (en) Tubulysin derivatives
US20210137955A1 (en) Combination therapy for cancer treatment
CA3219236A1 (en) Exatecan derivatives and antibody-drug conjugates thereof
JP2018524403A5 (enExample)
JP2012515225A5 (enExample)
KR20230142753A (ko) Cbl-b 억제제로서의 락탐
JP2011500801A5 (enExample)
FI3796912T3 (fi) Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön
RU2018129308A (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
EP4217398B1 (en) Anti-c-met antibody drug conjugates
PT2049522E (pt) Inibidores do vírus da hepatite c
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
WO2017214462A4 (en) Anti-cd98 antibodies and antibody drug conjugates
JP2016539138A5 (enExample)
WO2020211672A1 (en) Cd73 inhibitors
JP2007515419A5 (enExample)
CA3264543A1 (en) ANTIBODY-DRUG ANTI-ATTACK CONJUGATES RELATED TO 6 HOMOLOGUES
AU2021314401A1 (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos
RU2004128465A (ru) Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
AU2020348825B2 (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
RU2020120043A (ru) Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7